Literature DB >> 11028681

Brain lipoprotein metabolism and its relation to neurodegenerative disease.

M Danik1, D Champagne, C Petit-Turcotte, U Beffert, J Poirier.   

Abstract

Lipoproteins are macromolecular complexes composed of lipids and proteins. The role of these complexes is to provide cells of the organism with lipids to be used as a source of energy, building blocks for biomembrane synthesis, and lipophilic molecules (e.g., steroid hormones and vitamin E) for other physiological purposes, such as cell signaling and antioxidative mechanisms. Lipoproteins also promote the cellular efflux of cholesterol for its disposal into bile. Thus, lipoproteins play an important role in the maintenance of lipid homeostasis throughout the organism. Accordingly, lipoprotein particles have been found circulating in blood, lymph, and interstitial fluid. Despite the existence of the blood-brain barrier, lipoprotein particles have been shown to be also present in the cerebrospinal fluid (CSF). Although a portion of their protein components may filter through the barrier from the vascular compartment, experimental evidence indicates that these particles originate from the nervous tissue. The other protein components include apolipoproteins E, J, and D, and these have been shown to be synthesized by cells within the central nervous system (CNS). Furthermore, it was shown that lipoprotein particles can be isolated from the conditioned medium of astrocytic cultures. The differences in size, structure, and composition of in vitro assembled particles compared with those isolated from the CSF suggest that the particles are modified following their secretion in vivo. This is supported by observations that lipoprotein-modifying enzymes and transfer proteins are also present within CNS tissue and CSF. The fate of CSF lipoproteins is unclear but is probably related to the turnover and clearance of lipids from the CNS or, alternatively, the particles may be recaptured and recycled back into the CNS tissue. The presence of several cell surface receptors for apoE-containing lipoproteins on ependymal cells, as well as on neurons and glial cells, supports this notion and suggests that the isolated brain possesses its own system to maintain local lipid homeostasis. This is further exemplified by the salvage and recycling of lipids shown to occur following a lesion in order to allow surviving neurons to sprout and reestablish lost synapses. Not much is currently known about lipoprotein metabolism in neurodegenerative diseases, but lipid alterations have been repeatedly reported in Alzheimer brains in which neuronal loss and deafferentation are major features. Although the mechanism underlying the link between the epsilon4 allele of the apolipoprotein E gene and Alzheimer's disease is presently unclear, it may well be postulated that it is related to disturbances in brain lipoprotein metabolism.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 11028681     DOI: 10.1615/critrevneurobiol.v13.i4.20

Source DB:  PubMed          Journal:  Crit Rev Neurobiol        ISSN: 0892-0915


  18 in total

Review 1.  The role of apolipoprotein E in Guillain-Barré syndrome and experimental autoimmune neuritis.

Authors:  Hong-liang Zhang; Jiang Wu; Jie Zhu
Journal:  J Biomed Biotechnol       Date:  2010-02-16

2.  Cerebrospinal fluid apolipoprotein E and phospholipid transfer protein activity are reduced in multiple sclerosis; relationships with the brain MRI and CSF lipid variables.

Authors:  Simona Vuletic; Hal Kennedy; John J Albers; Joep Killestein; Hugo Vrenken; Dieter Lütjohann; Charlotte E Teunissen
Journal:  Mult Scler Relat Disord       Date:  2014-07-01       Impact factor: 4.339

Review 3.  MicroRNAs: a connection between cholesterol metabolism and neurodegeneration.

Authors:  Leigh Goedeke; Carlos Fernández-Hernando
Journal:  Neurobiol Dis       Date:  2014-06-05       Impact factor: 5.996

4.  Gene expression analysis in schizophrenia: reproducible up-regulation of several members of the apolipoprotein L family located in a high-susceptibility locus for schizophrenia on chromosome 22.

Authors:  Michael L Mimmack; Margaret Ryan; Hajime Baba; Juani Navarro-Ruiz; Shuji Iritani; Richard L M Faull; Peter J McKenna; Peter B Jones; Heii Arai; Michael Starkey; Piers C Emson; Sabine Bahn
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-02       Impact factor: 11.205

Review 5.  Dietary lipids in the aetiology of Alzheimer's disease: implications for therapy.

Authors:  Janelle L Cooper
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

6.  ABCA1/ApoE/HDL Pathway Mediates GW3965-Induced Neurorestoration After Stroke.

Authors:  Xu Cui; Michael Chopp; Zhenggang Zhang; Rongwen Li; Alex Zacharek; Julie Landschoot-Ward; Poornima Venkat; Jieli Chen
Journal:  Stroke       Date:  2016-12-27       Impact factor: 7.914

7.  Z-Guggulsterone Improves the Scopolamine-Induced Memory Impairments Through Enhancement of the BDNF Signal in C57BL/6J Mice.

Authors:  Zhuo Chen; Chao Huang; Wenbin Ding
Journal:  Neurochem Res       Date:  2016-09-28       Impact factor: 3.996

8.  Apolipoprotein E and cholesterol in aging and disease in the brain.

Authors:  Elena Posse de Chaves; Vasanthy Narayanaswami
Journal:  Future Lipidol       Date:  2008-10

9.  Association of 3'-UTR polymorphisms of the oxidised LDL receptor 1 (OLR1) gene with Alzheimer's disease.

Authors:  J-C Lambert; E Luedecking-Zimmer; S Merrot; A Hayes; U Thaker; P Desai; A Houzet; X Hermant; D Cottel; A Pritchard; T Iwatsubo; F Pasquier; B Frigard; P M Conneally; M-C Chartier-Harlin; S T DeKosky; C Lendon; D Mann; M I Kamboh; P Amouyel
Journal:  J Med Genet       Date:  2003-06       Impact factor: 6.318

10.  Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease.

Authors:  Carlos Cruchaga; John S K Kauwe; Petra Nowotny; Kelly Bales; Eve H Pickering; Kevin Mayo; Sarah Bertelsen; Anthony Hinrichs; Anne M Fagan; David M Holtzman; John C Morris; Alison M Goate
Journal:  Hum Mol Genet       Date:  2012-07-20       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.